Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDasom LeeKKKendall KozyCLClaire Lohman

Discussion

Loading...

Member takes

Overview

Interim findings reveal Axi-Cel-2 enhances progression-free survival and reduces toxicity in relapsed large B-cell lymphoma.

Key Points

  • Overall response rate reached 90.9% among 11 patients receiving Axi-Cel-2 infusion, indicating high efficacy.
  • Median follow-up of 5.8 months showed a 78.7% progression-free survival rate for Axi-Cel-2 treated patients.
  • Assessment using molecular responses from circulating tumor DNA demonstrated 60% minimal residual disease negativity at one-month follow-up.
  • Results suggest Axi-Cel-2 may reduce CAR-T exhaustion, enhancing therapeutic efficacy in high-risk patients.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8d0https://doi.org/10.1182/blood-2025-671
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  2. 2Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial2025
  3. 3Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  4. 4Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  5. 5Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE2025 · 2 citations